Gagnadoux F, Diot P, Marchand S, Thompson R, Dieckman K, Lemarié E, Varaigne F, Maurage C, Baulieu J L, Rolland J C
Service de Pneumologie, CHU Bretonneau, Tours.
Rev Mal Respir. 1996;13(1):55-60.
The objective of this study was to quantify the deposition in the lung of a Colistine aerosol generated using a pneumatic nebuliser (Pari LL(R) equipped with a Pari Master, Pari, Germany) and to compare this with the results obtained with an ultrasonic nebuliser (DP100, DP Medical, France) in four subjects suffering from cystic fibrosis being colonised with Pseudomonas aeruginosa. To quantify the pulmonary deposition of the aerosols we have used an indirect isotopic method which consists in assimilating the kinetics of the molecules studied with a serum albumin tagged with Technetium 99m (Tc99mm) and added to a preparation of Colistine. We have previously verified that the addition of a radioactive tracer does not change the normal distribution or dynamics of the medication within the aerosol and the radioactive counter linked to the tracer reflects the mass of the medicament. The pulmonary deposition was expressed as a percentage of the nebuliser dose. A regional analysis of the deposition (central, peripheral, superior and inferior) was carried out and in central deposition compared to the periphery (C/P) and superior compared to inferior (S/I) were calculated. With the DP100 nebuliser the pulmonary deposition of the aerosol was very reproducible from one patient to another, varying only between 9.5 to 14 percent of the nebuliser dose. With the Pari LL the fraction deposited varied more from one patient to another from 5.6 to 27% of the nebuliser dose. In three of four patients, the pulmonary deposition was superior or equal to that obtained with the ultrasonic nebuliser. The patients whose pulmonary deposition was inferior, using the pneumatic nebuliser, was the youngest in the group and co-ordinately poorly the triggering of the nebuliser with the beginning of inspiration. With the two nebulisers, the pulmonary deposition of Colisitine was very heterogeneous throughout the pulmonary parenchyma. The mean of the ratio C/P and S/I obtained in all four patients was identical (1.35 an 0.86 respectively), indicating a deposition of the aerosol which was predominantly central and inferior but was distributed equally in the peripheral parts of the lung. Pneumatic nebulisers offer a reliable alternative notably for domiciliary treatment for Colistine aerosols in patients suffering from cystic fibrosis. In younger patients who have not yet acquired good motor co-ordination, nebulisers which function continuously or are triggered by inspiration seem to be the preferred choice.
本研究的目的是对使用气动雾化器(配备Pari Master的德国Pari LL(R))产生的多粘菌素气雾剂在肺部的沉积进行定量,并将其与在4例感染铜绿假单胞菌的囊性纤维化患者中使用超声雾化器(法国DP Medical的DP100)所获得的结果进行比较。为了定量气雾剂的肺部沉积,我们采用了一种间接同位素方法,该方法包括将所研究分子的动力学与用锝99m(Tc99mm)标记的血清白蛋白同化,并添加到多粘菌素制剂中。我们之前已经验证,添加放射性示踪剂不会改变气雾剂内药物的正常分布或动力学,并且与示踪剂相连的放射性计数器反映了药物的质量。肺部沉积以雾化器剂量的百分比表示。对沉积进行了区域分析(中央、外周、上部和下部),并计算了中央沉积与外周沉积的比值(C/P)以及上部沉积与下部沉积的比值(S/I)。使用DP100雾化器时,气雾剂的肺部沉积在不同患者之间具有很高的可重复性,仅在雾化器剂量的9.5%至14%之间变化。使用Pari LL时,沉积分数在不同患者之间变化更大,为雾化器剂量的5.6%至27%。在4例患者中的3例中,肺部沉积优于或等于使用超声雾化器时的沉积。使用气动雾化器时肺部沉积较差的患者是该组中最年轻的,并且在吸气开始时协调雾化器触发的能力较差。使用这两种雾化器时,多粘菌素在整个肺实质中的肺部沉积非常不均匀。在所有4例患者中获得的C/P和S/I比值的平均值相同(分别为1.35和0.86),表明气雾剂的沉积主要集中在中央和下部,但在肺的外周部分分布均匀。气动雾化器为囊性纤维化患者的多粘菌素气雾剂家庭治疗提供了一种可靠的替代方法。对于尚未获得良好运动协调性的年轻患者,持续工作或由吸气触发的雾化器似乎是首选。